Ranolazine: focusing on angina pectoris.
Chronic stable angina is common and is a difficult-to-manage problem when patients begin to fail conventional therapy especially when maximal revascularization has been provided. The most promising agent in development is ranolazine, a late sodium channel inhibitor and partial fatty oxidation inhibitor which has unique and desirable anti-ischemic and electrophysiologic properties. This agent is likely to become standard therapy for chronic stable angina and may play a future role in the management of acute coronary syndromes.
McCullough
Peter A
PA
Department of Medicine, Divisions of Cardiology, Nutrition and Preventive Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073, USA. pmc975@yahoo.com
D000083:Acetanilides; D000787:Angina Pectoris / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000069458:Ranolazine
D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine